ArticleAsian Pacific journal of cancer prevention : APJCP2025
Advancing Non-Invasive Genomic Detection of p53 Tumor Suppressor Mutations in Fecal and Tumor Tissues of Colorectal Cancer Patients in Makassar.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths. TP53 mutations are frequently observed in CRC. This study evaluates TP53 mutations in tissue and fecal samples from CRC patients in Makassar, Indonesia, assessing diagnostic utility.
methodsA cross-sectional study was conducted with 66 CRC patients. DNA from tumor and fecal samples was analyzed using PCR and sequencing. Statistical analysis used SPSS and Python. ROC analysis (AUC: 0.725, 95% CI: [insert CI]) and gradient boosting model (AUC: 0.93) were performed.
resultsTP53 mutations were found in 25.7% of tissue and 13.6% of fecal samples. Fecal TP53 detection showed sensitivity of 47%, specificity of 97%, and 85% accuracy with predictive modeling.
conclusionFecal-based TP53 mutation detection shows promise as a non-invasive biomarker for CRC. Despite high specificity, further validation is required to confirm its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.